Diverging from its status in melanoma and cholangiocarcinoma, where the primary genomic alteration of BAP1 occurs as a mutation, the predominant genomic alteration of BAP1 in pancreatic cancer is copy number loss (shallow deletion 26.03%, deep deletion 0.54%) (Fig. 1A). This evidence concerns the gene BAP1 and pancreatic neoplasm.